9DF Stock Overview
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Mindset Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.49 |
| 52 Week High | CA$0.53 |
| 52 Week Low | CA$0.13 |
| Beta | -0.098 |
| 1 Month Change | -1.20% |
| 3 Month Change | 43.31% |
| 1 Year Change | 58.78% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9DF | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.0% | 2.6% | 2.5% |
| 1Y | 58.8% | -22.6% | 6.0% |
Return vs Industry: 9DF exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 9DF exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 9DF volatility | |
|---|---|
| 9DF Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9DF's share price has been volatile over the past 3 months.
Volatility Over Time: 9DF's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | James Lanthier | www.mindsetpharma.com |
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
Mindset Pharma Inc. Fundamentals Summary
| 9DF fundamental statistics | |
|---|---|
| Market cap | €51.15m |
| Earnings (TTM) | -€4.17m |
| Revenue (TTM) | €5.29m |
9.7x
P/S Ratio-12.3x
P/E RatioIs 9DF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9DF income statement (TTM) | |
|---|---|
| Revenue | CA$7.75m |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$7.75m |
| Other Expenses | CA$13.86m |
| Earnings | -CA$6.11m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 100.00% |
| Net Profit Margin | -78.82% |
| Debt/Equity Ratio | 0% |
How did 9DF perform over the long term?
See historical performance and comparison